Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2008-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularheartfailuretherapygreater
  Phrases that lowered it: relevantscreeningdiseasesvisitclinical
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 14.3% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 7.8% (lowers risk) · Drug's FDA history
• Responsible party: not given (raises risk) · Design
• Minimum age: 45 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 76 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports marked serious: 79.9% (lowers risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Keywords listed: 5 (lowers risk) · Design
• Sponsor's past trials: 98 (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF NCT02780180 · started 2016 · scored riskier than 85% of active trials terminated
• Study to Investigate the Effects of Vitamin D Administration on Plasma Renin Activity in Patients With Stable Chronic Heart Failure NCT01092130 · started 2010 · scored riskier than 46% of active trials completed
• Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets NCT02522208 · started 2015 · scored riskier than 29% of active trials completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients NCT03066804 · started 2017 · scored riskier than 61% of active trials completed
• Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) NCT03988634 · started 2019 · scored riskier than 84% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.